Erik Manting
Chief Executive Officer en MENDUS AB .
Fortuna: 60 707 $ al 31/03/2024
Perfil
Dr. Erik Manting is an Independent Director at TransCode Therapeutics, Inc. and a Chief Executive & Business Officer at Mendus AB.
He is on the Board of Directors at TransCode Therapeutics, Inc. and Synerkine Pharma BV.
Dr. Manting was previously employed as a Founder by Bioentrepreneur BV, a Chief Executive Officer by DCPrime BV, an Executive Director-Life Sciences & Healthcare by Kempen & Co. NV, and an Analyst by Rabo Securities NV.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
MENDUS AB
0.21% | 31/12/2022 | 1 442 312 ( 0.21% ) | 60 707 $ | 31/03/2024 |
| 13/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Erik Manting
| Empresas | Cargo | Inicio |
|---|---|---|
| MENDUS AB | Chief Executive Officer | 16/03/2021 |
| TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 20/12/2020 |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 01/03/2019 |
Antiguos cargos conocidos de Erik Manting.
| Empresas | Cargo | Fin |
|---|---|---|
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 01/12/2020 |
Kempen & Co. NV
 Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01/09/2017 |
| Rabo Securities NV | Analyst-Equity | 14/09/2005 |
| Bioentrepreneur BV | Founder | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MENDUS AB | Health Technology |
| Empresas privadas | 6 |
|---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
| Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| TransCode Therapeutics, Inc. | |
| Bioentrepreneur BV |
- Bolsa de valores
- Insiders
- Erik Manting
